Sustained Release Excipients Market Size, Share & Trends Analysis
Report and Segment Forecast, 2026| Grand View Research, Inc
“Rising number of patent expirations and soaring need for pediatric and geriatric
dosage forms are providing a boost to the growth of the sustained release
excipients market.”
The global Sustained Release Excipients Market size is expected to reach USD 1.6 billion by 2026 at a 7.1%
CAGR during the forecast period, according to a new report by Grand View Research, Inc. Increasing focus on
novel drug delivery R&D and rising adoption of extended release formulations for treatment of chronic diseases
are major factors driving the market.
Use of sustained release drug formulations provides patients relief from these symptoms and helps maintain
desired therapeutic drug levels in the body. In comparison to conventional drugs, sustained drug release
technologies provide a wide range of benefits. Reduced dosage frequency, improved patient compliance,
maintenance of constant level of drug in blood plasma, lower instances of toxicity due to overdose, and higher
cost-effectiveness in the long run are some of the major advantages of using this technology.
Global rise in incidence of chronic and infectious diseases has also resulted in antibiotic resistance, which
negatively affects the market for conventional dosage forms. Thus, alternative methods to manage and treat
these diseases are being implemented. Use of sustained release formulations has been widely accepted among
physicians in order to combat antibiotic resistance. Since these formulations create desired therapeutic drug
levels in blood plasma and reduce dosage frequency, they are the preferred choice of formulation among
physicians, which increases their demand.
To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/sustained-release-excipients-market
Further key findings from the report suggest:
Follow Us:

Polymers formed the largest revenue grossing segment by product type in 2017 and is anticipated to
grow at a lucrative rate during the forecast period. This is due to its high adoption in sustained release
formulations as they provide greater strength and improved shelf-life

In terms of route of administration, the oral segment held the dominant share in 2017 and is projected
to witness steady growth to retain its lead throughout the forecast period

Transdermal technology is expected to exhibit the highest CAGR during the forecast period owing to its
escalating usage. It minimizes various limitations associated with oral and parenteral route of
administrations

North America dominated the overall market in 2017 due to well-developed research infrastructure and
presence of leading pharmaceutical and biopharmaceutical companies

Asia Pacific is spearheading revenue growth, with Japan, China, and India at the forefront

Some of the key companies in the market are Coating Place, Inc.; Depomed, Inc.; Corium International,
Inc.; Capsugel; Aradigm Corporation; Orbis Biosciences, Inc.; and Alkermes plc.
Grand View Research has segmented the global sustained release excipients market on the basis of product,
route of administration, technology, and region:
Sustained Release Excipients Product Outlook (Revenue, USD Million, 2015 - 2026)

Gelatin

Polymers

Minerals

Sugars

Alcohol

Chitosan
Sustained Release Excipients Route of Administration Outlook (Revenue, USD Million, 2015 - 2026)

Oral

Intramuscular

Subcutaneous

Transdermal

Vaginal
Follow Us:

Ophthalmic

Intravenous

Others
Sustained Release Excipients Technology Outlook (Revenue, USD Million, 2015 - 2026)

Targeted Delivery

Micro Encapsulation

Wurster Technique

Transdermal

Implants

Coacervation

Others
Sustained Release Excipients Regional Outlook (Revenue, USD Million, 2015 - 2026)




North America
o
U.S.
o
Canada
Europe
o
Germany
o
U.K.
Asia Pacific
o
Japan
o
China
o
India
Latin America
Follow Us:
o
Brazil
o
Mexico

Middle East & Africa
o
Follow Us:
South Africa
Table of Content of Sustained Release Excipients Market
Chapter 1 Executive Summary
Chapter 2 Research Methodology
2.1 Country-wise Market: Base Estimates
2.2 Global Market: CAGR Calculation
2.3 Region-based Segment Share Calculation
2.4 Research Scope & Assumptions
2.5 List of Data Sources
2.5.1 Data for primary interviews, by sources
2.5.2 Data for primary interviews, by region
2.6 Market Snapshot
Chapter 3 Sustained Release Excipients Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Increased benefits over conventional dosage forms
3.2.2 Antibiotic resistance
3.2.3 Necessity of pediatric and geriatric sustained release dosage forms
3.2.4 Increased acceptance due to nature of dosage forms
3.3 Market Restraint Analysis
3.3.1 Drug toxicity due to dose dumping
3.3.2 Need for high dose of API
3.4 Market Challenge Analysis
3.4.1 Patient education and counselling
3.4.2 Higher cost of sustained release systems in comparison to conventional pharmaceutical
formulations
3.5 Market Opportunity Analysis
3.5.1 Development cost-efficient dosage forms
3.5.2 Minimization of hepatic first pass elimination
3.6 Market Opportunity Analysis
3.6.1 Key opportunities prioritized, by product
3.6.2 Key opportunities prioritized, by route of administration
Follow Us:
3.6.3 Key opportunities prioritized, by technology
3.7 Sustained Release Excipients - SWOT Analysis, by Factor (Political & Legal, Economic and
Technological)
3.8 Industry Analysis - Porter’s
3.9 Major Excipients Used in Sustained Release Formulations
Chapter 4 Sustained Release Excipients Market: Product Estimates & Trend Analysis
4.1 Sustained Release Excipients Market: Product Movement Analysis
4.2 Gelatin
4.2.1 Gelatin market, 2015 - 2026 (USD Million)
4.3 Polymers
4.3.1 Polymers market, 2015 - 2026 (USD Million)
4.4 Minerals
4.4.1 Minerals market, 2015 - 2026 (USD Million)
4.5 Sugars
4.5.1 Sugars market, 2015 - 2026 (USD Million)
4.6 Alcohol
4.6.1 Alcohol market, 2015 - 2026 (USD Million)
4.7 Chitosan
4.7.1 Chitosan market, 2015 - 2026 (USD Million)
Chapter 5 Sustained Release Excipients Market: Route of Administration Estimates & Trend Analysis
5.1 Sustained release excipients market: Route of administration movement analysis
5.2 Oral
5.2.1 Oral market, 2015 - 2026 (USD Million)
5.3 Intramuscular
5.3.1 Intramuscular market, 2015 - 2026 (USD Million)
5.4 Subcutaneous
5.4.1 Subcutaneous market, 2015 - 2026 (USD Million)
5.5 Transdermal
5.5.1 Transdermal market, 2015 - 2026 (USD Million)
5.6 Vaginal
5.6.1 Vaginal market, 2015 - 2026 (USD Million)
Follow Us:
5.7 Ophthalmic
5.7.1 Ophthalmic market, 2015 - 2026 (USD Million)
5.8 Intravenous
5.8.1 Intravenous market, 2015 - 2026 (USD Million)
5.9 Others
5.9.1 Others market, 2015 - 2026 (USD Million)
Chapter 6 Sustained Release Excipients Market: Technology Estimates & Trend Analysis
6.1 Sustained release excipients market: Technology movement analysis
6.2 Targeted Delivery
6.2.1 Targeted delivery market, 2015 - 2026 (USD Million)
6.3 Microencapsulation
6.3.1 Micro encapsulation market, 2015 - 2026 (USD Million)
6.4 Wurster Technique
6.4.1 Wurster technique market, 2015 - 2026 (USD Million)
6.5 Transdermal
6.5.1 Transdermal market, 2015 - 2026 (USD Million)
6.6 Implants
6.6.1 Implants market, 2015 - 2026 (USD Million)
6.7 Coacervation
6.7.1 Coacervation market, 2015 - 2026 (USD Million)
6.8 Others
6.8.1 Others market, 2015 - 2026 (USD Million)
Chapter 7 Sustained Release Excipients Market: Regional Estimates & Trend Analysis, by Product, Route of
Administration, and Technology
7.1 Sustained release excipients market share by region, 2017 & 2026
7.2 North America
7.2.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.2.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.2.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.2.4 U.S.
7.2.4.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
Follow Us:
7.2.4.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.2.4.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.2.5 Canada
7.2.5.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.2.5.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.2.5.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.3 Europe
7.3.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.3.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.3.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.3.4 Germany
7.3.4.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.3.4.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.3.4.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.3.5 U.K.
7.3.5.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.3.5.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.3.5.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.4 Asia Pacific
7.4.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.4.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.4.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.4.4 Japan
7.4.4.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.4.4.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.4.4.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.4.5 China
7.4.5.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.4.5.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.4.5.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.4.6 India
Follow Us:
7.4.6.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.4.6.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.4.6.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.5 Latin America
7.5.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.5.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.5.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.5.4 Brazil
7.5.4.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.5.4.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.5.4.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.5.5 Mexico
7.5.5.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.5.5.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.5.5.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.6 Middle East & Africa (MEA)
7.6.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.6.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.6.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
7.6.4 South Africa
7.6.4.1 Sustained release excipients market, by product, 2015 - 2026 (USD Million)
7.6.4.2 Sustained release excipients market, by route of administration, 2015 - 2026 (USD Million)
7.6.4.3 Sustained release excipients market, by technology, 2015 - 2026 (USD Million)
Chapter 8 Competitive Landscape: Sustained Release Drugs
8.1 Teva Pharmaceutical Industries Ltd.
8.1.1 Company overview
8.1.2 Financial performance
8.1.3 Product benchmarking
8.1.4 Strategic initiatives
8.2 Mylan N.V.
8.2.1 Company overview
Follow Us:
8.2.2 Financial performance
8.2.3 Product benchmarking
8.2.4 Strategic initiatives
8.3 Valeant Pharmaceuticals International, Inc.
8.3.1 Company overview
8.3.2 Financial performance
8.3.3 Product benchmarking
8.3.4 Strategic initiatives
8.4 Pfizer, Inc.
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Product benchmarking
8.4.4 Strategic initiatives
8.5 Sun Pharmaceutical Industries Ltd.
8.5.1 Company overview
8.5.2 Financial performance
8.5.3 Product benchmarking
8.5.4 Strategic initiatives
8.6 Novartis AG
8.6.1 Company overview
8.6.2 Financial performance
8.6.3 Product benchmarking
8.6.4 Strategic initiatives
8.7 AstraZeneca
8.7.1 Company overview
8.7.2 Financial performance
8.7.3 Product benchmarking
8.7.4 Strategic initiatives
8.8 GlaxoSmithKline plc
8.8.1 Company overview
8.8.2 Financial performance
Follow Us:
8.8.3 Product benchmarking
8.9 Allergan plc
8.9.1 Company overview
8.9.2 Financial performance
8.9.3 Product benchmarking
8.9.4 Strategic initiatives
8.10 Janssen Pharmaceuticals, Inc.
8.10.1 Company overview
8.10.2 Financial performance
8.10.3 Product benchmarking
8.10.4 Strategic initiatives
8.11 Mayne Pharma Group Limited
8.11.1 Company overview
8.11.2 Financial performance
8.11.3 Product benchmarking
8.11.4 Strategic initiatives
Chapter 9 Competitive Landscape: Sustained Release Technology
9.1 Depomed, Inc.
9.1.1 Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.2 Coating Place, Inc.
9.2.1 Company overview
9.2.2 Product benchmarking
9.3 Corium International, Inc.
9.3.1 Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.4 Orbis Biosciences, Inc.
Follow Us:
9.4.1 Company overview
9.4.2 Product benchmarking
9.5 Capsugel
9.5.1 Company overview
9.5.2 Product benchmarking
9.5.3 Strategic initiatives
9.6 Aradigm Corporation
9.6.1 Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.7 Alkermes plc
9.7.1 Company Overview
9.7.2 Financial Performance
9.7.3 Product Benchmarking
9.7.4 Strategic Initiatives
Chapter 10 Product Pipeline Analysis
10.1 Pipeline Development and Clinical Trials
10.1.1 Clinical Trials in Phase 4
Follow Us:
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed business decisions, the company offers
market intelligence studies ensuring relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: [email protected]
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Follow Us:

The global sustained release excipients market size is expected to reach USD 1.6 billion by 2026 at a 7.1% CAGR during the forecast period, according to a new report by Grand View Research, Inc.